Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05903924 · ClinicalTrials.gov registry record · Phase 3
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
A Phase 3 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 316
- Enrollment target
NCT05903924 is a Phase 3 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 316 participants.
The verdict
NCT05903924, a Phase 3 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 316 participants
- Enrollment target
Study Summary
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel
Interventions
- DRUG Placebo
- DRUG Tradipitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 316 participants |
| Start Date | 2023-09-09 |
| Est. Completion | 2024-04-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05903924
The ClinicalTrials.gov registry entry for NCT05903924 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 316 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05903924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05903924 about?
NCT05903924 is a clinical study titled "Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness". A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel
What is the current status of trial NCT05903924?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 316 participants. The study started on 2023-09-09. Estimated completion is 2024-04-24.
What interventions are being tested in trial NCT05903924?
The interventions under investigation include: Placebo (DRUG), Tradipitant (DRUG).
Who is sponsoring clinical trial NCT05903924?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.